Unknown

Dataset Information

0

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.

ABSTRACT: In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.

SUBMITTER: Salvadori N 

PROVIDER: S-EPMC6579954 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.

Salvadori Nicolas N   Fan Bo B   Teeyasoontranon Waralee W   Ngo-Giang-Huong Nicole N   Phanomcheong Siriluk S   Luvira Anita A   Puangsombat Achara A   Suwannarat Arunrat A   Srirompotong Ussanee U   Putiyanun Chaiwat C   Cressey Tim R TR   Decker Luc L   Khamduang Woottichai W   Harrison Linda L   Tierney Camlin C   Shepherd John A JA   Kourtis Athena P AP   Bulterys Marc M   Siberry George K GK   Jourdain Gonzague G  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20190601 1

In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822. ...[more]

Similar Datasets

Unknown Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
| S-EPMC4551007 | biostudies-literature
Unknown Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
| S-EPMC9297643 | biostudies-literature
Unknown Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.
| S-EPMC6256809 | biostudies-literature
Unknown Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.
| S-EPMC5890741 | biostudies-literature
Unknown Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects.
| S-EPMC8020360 | biostudies-literature
Unknown Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.
| S-EPMC3855348 | biostudies-literature
Unknown Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
| S-EPMC4577040 | biostudies-literature
Unknown Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
| S-EPMC4879396 | biostudies-literature
Unknown Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B.
| S-EPMC4499796 | biostudies-literature
Unknown Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis.
| S-EPMC7820648 | biostudies-literature